QGEN - Qiagen N.V. Short-Term Debt to Capital

QGEN (Qiagen N.V.) - company brandmark

The short-term debt-to-equity ratio on the GURU.Markets chart correlates with the effective global distribution of reagents by Qiagen N.V. (QGEN). The value 0.01 describes the current level of debt load supported by plant capacities in the US and Germany. Business resilience is ensured by patent protection and the deep integration of test systems into clinics, which creates significant barriers to entry for new market players.

Short-Term Indebtedness to Equity: Qiagen NV (QGEN) for 07/04/2022 - 11/01/2026

Analytical breakdowns for Qiagen N.V.

- stock value and consensus price forecast:
Price Chart Qiagen Group|QGEN - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Qiagen NV|QGEN - Enterprise Value
- book capitalization information:
Net Assets per Single Share Qiagen|QGEN - Book Value of Business|Market Capitalization to Book Value Ratio qiagen.com|QGEN - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Capital Qiagen N.V.|QGEN - Long-Term Debt to Capital|Short-Term Debt to Capital Qiagen|QGEN - Company Total Indebtedness|Debts to Book Capitalization Qiagen NV|QGEN - Long-Term Debt|Company Short-Term Debt Qiagen|Quick Liquidity Indicator qiagen.com
- company profitability and valuation multiples indicators:
QGEN - Final Profit
Initial company analysis:Qiagen Group
Brand item of qiagen.com

Qiagen N.V. is aggressively competing for the laboratory market amid intense pressure from healthcare behemoths. The current value of 0.01 reflects the ratio of short-term liabilities to equity, determining financial stability during equipment procurement. This metric measures the business's dependence on rapid debt repayment to prevent the risk of cash flow gaps. Analyzing the dynamics of short-term loans relative to equity allows for the timely detection of balance sheet strain.

Competitors of Qiagen N.V. (QGEN)

Short-Term Debt to Equity Tempus AI (TEM)|Isis Pharmaceuticals - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital RGEN (Repligen Corporation)|Short-Term Debt to Capital aviditybiosciences.com RNA|CRSP - Short-Term Debt to Equity|Short-Term Indebtedness to Equity GeneDx Holdings (WGS)|RARE: Short-Term Debt to Capital|BEAM - Short-Term Debt to Capital Coefficient|SRPT (Sarepta Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital twistbioscience.com|Short-Term Debt to Capital TXG|Intellia Therapeutics Inc (NTLA) - Short-Term Indebtedness to Equity|Short-Term Debt to Capital STOK (Stoke)|BioLife (BLFS) - Current Liabilities to Capital|WVE - Short-Term Debt to Equity|MAZE (mazetx.com) - Short-Term Debt to Capital Ratio|SION (Sionna Therapeutics) - Short-Term Debt to Equity Ratio|Prime Medicine Inc - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Taysha|Short-Term Debt to Capital Ratio QURE (uniQure Pharma)|Short-Term Debt to Equity Ratio MGTX (MeiraGTx Holdings plc)|Short-Term Debt to Capital Coefficient regenxbio.com|Solid Biosciences - Short-Term Debt to Equity Ratio|Ocugen Inc - Short-Term Debt to Equity|PACB: Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Benitec Corp BNTC|Design Therapeutics (DSGN) - Short-Term Debt to Equity|Short-Term Indebtedness to Equity rocketpharma.com RCKT|FDMT (4D Molecular Therapeutics, Inc.) - Short-Term Debt to Capital|LXEO - Short-Term Indebtedness to Equity|Short-Term Debt to Capital KRRO|EDIT - Current Liabilities to Capital|Short-Term Debt to Equity Silence Therapeutics SLN|PRQR: Short-Term Debt to Capital Ratio|Codexis Bio - Short-Term Debt to Capital|SGMO (Sangamo Therapeutics Inc.) - Short-Term Debt to Capital Ratio|nautilus.bio (NAUT) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio MGX|DTIL (Precision BioSciences) - Short-Term Debt to Capital|Short-Term Debt to Capital Generation Bio Corp|Short-Term Debt to Equity Boundless Bio (BOLD)|exicuretx.com (XCUR) - Short-Term Indebtedness to Equity|Short-Term Debt to Capital IMNN (Imunon)|Short-Term Debt to Capital Coefficient Phio Pharmaceuticals Corp (PHIO)|Mustang Bio Corp - Short-Term Debt to Capital|RNAZ - Short-Term Debt to Capital|BNGO: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Applied DNA Sciences Inc APDN|BLUE (Bluebird Bio) - Short-Term Debt to Capital|Current Liabilities to Capital ImmunoPrecise IPA|Short-Term Debt to Equity Omega Therapeutics (OMGA)|singulargenomics.com - Short-Term Debt to Capital Ratio|Regulus Therapeutics Inc. - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SYRS|TBIO - Short-Term Debt to Equity|TCON (TRACON Pharmaceuticals, Inc) - Short-Term Debt to Capital Ratio|UBX (Unity Biotechnology) - Short-Term Debt to Equity Ratio